Blue Owl holds 3.19% stake in Context Therapeutics
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Blue Owl Capital Holdings LP reported beneficial ownership of common stock of Context Therapeutics Inc. in Amendment No. 3 to its Schedule 13G. Blue Owl holds 2,934,015 shares of common stock, representing 3.19% of the class, based on 91,879,177 shares outstanding as of May 4, 2026.
Blue Owl has sole voting power and sole dispositive power over all 2,934,015 shares, with no shared voting or dispositive power. The ownership is now reported as 5 percent or less of the class, and Blue Owl disclaims that the report constitutes an admission of beneficial ownership for certain legal purposes.
Key Figures
Key Terms
beneficially owned financial
Sole Voting Power financial
Sole Dispositive Power financial
Percent of class financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Is Blue Owl Capital Holdings still a 5% beneficial owner of Context Therapeutics (CNTX)?
AI-generated analysis. How Rhea-AI works. Not financial advice.